In a report released today, Vikram Purohit from Morgan Stanley maintained a Buy rating on RegenXBio (RGNX - Research Report), with a price target of $46.00. The company's shares opened today at $34.88.According to TipRanks, Purohit is an analyst with an average return of -17.6% and a 30.95% success rate. Purohit covers the Healthcare sector, focusing on stocks such as RegenXBio, Axsome Therapeutics, and Arcutis Biotherapeutics.In addition to Morgan Stanley, RegenXBio also received a Buy from Berenberg Bank's Caroline Palomeque in a report issued on August 4. However, on the same day, SVB Securities reiterated a Hold rating on RegenXBio (NASDAQ: RGNX).
https://www.tipranks.com/news/blurbs/morgan-stanley-remains-a-buy-on-regenxbio-rgnx?utm_source=advfn.com&utm_medium=referral
REGENXBIO (NASDAQ:RGNX)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more REGENXBIO Charts.
REGENXBIO (NASDAQ:RGNX)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more REGENXBIO Charts.